N-heterocyclic compounds and methods of use thereof

NZ834905AUndetermined Publication Date: 2025-07-31LIFEMINE THERAPEUTICS INC
0 Cites 0 Cited by

Patent Information

Application Number
NZ834905
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-24
Filing Date
2025-01-21
Publication Date
2025-07-31

AI Technical Summary

Technical Problem

Current calcineurin inhibitors (CNIs) used for treating inflammatory-related diseases and disorders, such as tacrolimus, are associated with significant side effects like nephrotoxicity, CNS toxicity, and patient nonadherence due to adverse reactions, necessitating the development of safer alternatives.

Method used

Development of novel N-heterocyclic compounds, particularly those with a core quinoline or isoquinoline moiety, that inhibit calcineurin activity to treat inflammatory-related diseases and disorders, offering improved safety profiles and patient adherence.

Benefits of technology

The novel N-heterocyclic compounds demonstrate reduced nephrotoxicity, improved bioavailability, and minimized food effects, enhancing patient compliance and therapeutic efficacy in treating conditions like kidney transplant rejection and inflammatory disorders.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application provides novel N-heterocyclic compounds, such as quinoline or isoquinoline compounds, preferably quinazoline compounds, as calcineurin inhibitors (CNIs,) that provide improved safety profiles, and the pharmaceutical composition and formulation thereof, as well as a method of using the N-heterocyclic compounds for the treatment of, inter alia, an inflammatory-related disease or disorder.
Need to check novelty before this filing date? Find Prior Art